Global Anti-Infective Agents Market 2021 (Includes Business Impact of COVID-19)

  • TBI742891
  • September 16, 2021
  • Global
  • 149 pages
  • Market.US
                                              

Report updated on 11th September, 2021: Global Anti-Infective Agents Market 2021 (Includes Business Impact of COVID-19)

Global Anti-Infective Agents Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2030 is a recent report generated by Trusted Business Insights. The global anti-infective agents market report has been segmented on the basis of type, indication, distribution channel, and region. Request Covid - 19 Impact The global Anti-Infective Agents market size was valued at USD $ 236.44 billion in 2020 and is projected to reach USD $330.31 billion by 2030 is anticipated to expand at a CAGR of 6.80% over the forecast period from 2020 to 2030.

Global Anti-Infective Agents Market: Overview

Anti-infective agents are drugs used to prevent infectious organisms or agents by inhibiting or killing in order to prevent the spreading the infection, prior to their discovery agents such as mercury and arsenic. In which, the infection causing micro-organisms includes virus, bacteria, viroids, fungi, and macroparasites.

Global Anti-Infective Agents Market: Dynamics

increasing the number of aging population coupled with rising prevalence of infectious diseases such as H1N1, HIV, and Ebola virus are primary factors expected to boost demand for anti-infective agents over the forecast period. In addition, increasing demand for anti-infective drugs across the globe owing to rising frequency rates of irresistible sicknesses is another factor estimated to drive the growth of the anti-infective agents market. Development of new multi-drug resistance against micro-organisms is another factor expected to propel the global anti-infective agents market. Factors projected to restrain the growth of the global anti-infective agents market includes high research and development cost, competition among generic manufacturers, and lack of awareness in developing regions. Moreover, growing technological advancements in the healthcare infrastructure and rising funding from the government for the R&D activities related to the development of new drugs are expected to create lucrative growth opportunities in the global anti-infective agents market.

Global Anti-Infective Agents Market: Segment Analysis

Among the type segments, the antiviral segment is projected to register moderate growth rate in the global anti-infective agents market. The antibacterial segment is projected to register the significant growth in the coming year, owing to the availability of the antibacterial agents as compared to other agents. Among the indication segments, the pneumonia segment is projected to register moderate growth rate in the global market. Among the distribution channel segments, the hospital pharmacy segment is expected to account for a major share in the global market. Whereas, the online sales segment is projected to be the fastest growing segment in the global anti-infective agents market, owing to convenience, flexibility, and comfort for consumers as compared to other distribution channels.

Global Anti-Infective Agents Market: Region Analysis

The market in North America is expected to account for the highest revenue share in the global market, followed by Europe. Increasing aging population, growing incidence of infectious diseases, and availability of non-prescription anti-infective agents is projected to drive the growth of the anti-infective agents market in North America. In addition, the favorable reimbursement policies from governments of countries in this region is estimated to drive the growth of the North America anti-infective agents market. Asia Pacific market is expected to register a significant growth rate in the global market, owing to the rapid development of healthcare infrastructure, and rising awareness in healthcare professionals and patient pool support the rapid growth of the market in this region.

Below are the active patents related to Anti-Infective Agents Market.

Patent Number: US20050256502A1 Anti-infective central venous catheter with diffusion barrier layer Abstract A catheter extending from a distal end which, when in an operative position is inserted within a body of a patient, to a proximal end, the catheter comprising a charge holding cavity to which a therapeutic compound is to be supplied and a wall including inner and outer portions, an inner surface of the inner portion surrounding the charge holding cavity with an outer portion surrounding at least a portion of an outer surface of the inner portion, wherein the inner portion is formed so that a first diffusion rate of the therapeutic compound therethrough is different from a second diffusion rate through the outer portion. Application filed Date: 2005-06-28 Application Granted Date: 2011-03-01 Current Assignee: Boston Scientific Scimed Inc

Global Anti-Infective Agents Market Segmentation:

Segmentation by Type:
  • Antibacterial
  • Antifungal
  • Antiviral
Segmentation by Indication:
  • Pneumonia
  • Dermatophytosis
  • Aspergillosis
  • Candidiasis
  • Hepatitis Virus Infection
  • Methicillin-resistant Staphylococcus Aureus (MRSA)
  • Sepsis
  • Tuberculosis
  • HIV Infection
  • Respiratory Virus Infection
  • Others
Segmentation by Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Sales

Key Market Players included in the report:

  • Abbott Laboratories
  • Alcon Pharmaceuticals Ltd.
  • Astellas Pharma, Inc.
  • AstraZeneca Plc.
  • Bayer Healthcare AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • Johnson & Johnson Services Inc.
  • Merck and Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi-Aventis S.A.

Below are the key development related to Anti-Infective Agents Market in 2020 and 2021.

April 2021: Pfizer Acquires Amplyx Pharmaceuticals. Deal expands anti-infectives pipeline with addition of novel antifungal Phase 2 candidate, Fosmanogepix (APX001). Opportunity to advance Pfizer’s expertise and deep heritage in infectious disease. Pfizer Inc. (NYSE: PFE) announced that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections. More than 1.5 million cases of invasive fungal infections occur worldwide each year, with mortality rates as high as 30-80% across infection typesi. Fosmanogepix has a novel mechanism of action with the potential to target fungal strains resistant to standard of care therapy. As there are only three classes of antifungal medications currently available, antifungal resistance can severely limit treatment options; a potential new therapeutic class may therefore be of importance for both physicians and patientsii. There has been no novel therapeutic class of antifungal therapies approved by the U.S. Food and Drug Administration (FDA) in nearly 20 years. Source October 2020: HitGen to Acquire Vernalis, a Leader in Structure-Based Drug Discovery. HITGEN (688222.SH) announces it has entered into a definitive agreement with Ligand Pharmaceuticals Inc. (NASDAQ: LGND) to acquire Vernalis (R&D) Limited, Cambridge, UK-based world leaders in fragment and structure-based drug discovery research. The acquisition is for the entire issued share capital of Vernalis (R&D) Limited, for $25M in cash. Source September 2020: Santen and U.S. Ophthalmic Company Eyevance Enter into Share Purchase Agreement. Santen Pharmaceutical Co., Ltd. (hereinafter "Santen") and Eyevance Holdings LLC announced that Santen Holdings U.S. Inc., a wholly-owned subsidiary of Santen, and Eyevance Holdings LLC entered into a share purchase agreement where Santen Holdings U.S. Inc. acquires all of outstanding shares of Eyevance Pharmaceuticals Holdings Inc. (hereinafter "Eyevance"). Source May 2020: Oragenics Acquires Noachis Terra Inc., To Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing “Spike Protein”. Oragenics, Inc. announced its acquisition of Noachis Terra Inc., following its entry into a stock purchase agreement, to develop and commercialize TerraCoV2, a vaccine candidate which could provide specific immunity from the novel coronavirus , the root cause of coronavirus disease 2019. Noachis Terra Inc., holds a worldwide, nonexclusive license to the TerraCoV2 vaccine candidate from the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institute of Health. The acquisition of Noachis Terra and its TerraCoV2 immunization product candidate represents its first step towards accessing pioneering technologies to reduce the global threat posed by COVID-19, which aligns with the company’s existing anti-infective programs. Source

Table of Contents
Chapter 1. Methodology and Scope                  1.1. Research Methodology                  1.2. Research Scope & Assumptions                  1.3. List of Data SourcesChapter 2. Executive SummaryChapter 3. Global Anti-Infective Agents Market Outlook                  3.1. Market Segmentation                  3.2. Market Size and Growth Prospects, 2016 - 2027                  3.3. Value Chain Analysis                  3.4. Market Dynamics                      3.4.1. Market driver analysis                      3.4.2. Market restraint analysis        
|  read more...

Request a sample

Fill below form to request a sample

Enquiry

Please fill this form to enquire before buying

Discount

You can request for discount regarding the report by using below form